Discover open access scientific publications

Search, annotate, share and cite publications

Publications by M.J. Dickinson

Cd20-TCB (Rg6026), a Novel “2:1” Format T-Cell-Engaging Bispecific Antibody, Induces Complete Remissions in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Hematological Oncology

English

Interim Report From a Phase 2 Multicenter Study of Tazemetostat, an Ezh2 Inhibitor, in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas

Hematological Oncology

English

Related publications

Cd19/Cd20-Redirected Bispecific Car T Cell Treatment in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Hematological Oncology

English

Clinical Activity of Regn1979, an Anti-Cd20 X Anti-Cd3 Bispecific Antibody (Ab) in Patients (Pts) With (W/) Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-Nhl)

Hematological Oncology

English

PRELIMINARY RESULTS OF ASTX660, a NOVEL NON-PEPTIDOMIMETIC cIAP1/2 AND XIAP ANTAGONIST, IN RELAPSED/REFRACTORY PERIPHERAL T-Cell LYMPHOMA AND CUTANEOUS T CELL LYMPHOMA

Hematological Oncology

English

Long-Term Outcome of Patients With Relapsed/Refractory B-Cell Non- Hodgkin Lymphoma Treated With Bispecific Antibody Blinatumomab in a Phase I Trial

Hematological Oncology

English

A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors

Clinical Cancer Research

Cancer Research

Oncology

2016

English

An Ongoing Phase 1/1b Trial Investigating Novel Treatment Regimens With Mosunetuzumab in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Hematological Oncology

English

PD-1 Blockade With Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

New England Journal of Medicine

Medicine

2015

English

Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (Aitl) and Cxcl12+ Peripheral T-Cell Lymphoma (Ptcl): Preliminary Results From a Phase 2 Study

Hematological Oncology

English

Anaplastic, T-Cell, Non-Hodgkin's Lymphoma Presenting With Haematuria

The Scientific World Journal

Environmental Science

2008

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by M.J. Dickinson

Cd20-TCB (Rg6026), a Novel “2:1” Format T-Cell-Engaging Bispecific Antibody, Induces Complete Remissions in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Interim Report From a Phase 2 Multicenter Study of Tazemetostat, an Ezh2 Inhibitor, in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas

Related publications

Cd19/Cd20-Redirected Bispecific Car T Cell Treatment in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Clinical Activity of Regn1979, an Anti-Cd20 X Anti-Cd3 Bispecific Antibody (Ab) in Patients (Pts) With (W/) Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-Nhl)

PRELIMINARY RESULTS OF ASTX660, a NOVEL NON-PEPTIDOMIMETIC cIAP1/2 AND XIAP ANTAGONIST, IN RELAPSED/REFRACTORY PERIPHERAL T-Cell LYMPHOMA AND CUTANEOUS T CELL LYMPHOMA

Long-Term Outcome of Patients With Relapsed/Refractory B-Cell Non- Hodgkin Lymphoma Treated With Bispecific Antibody Blinatumomab in a Phase I Trial

A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors

An Ongoing Phase 1/1b Trial Investigating Novel Treatment Regimens With Mosunetuzumab in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

PD-1 Blockade With Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (Aitl) and Cxcl12+ Peripheral T-Cell Lymphoma (Ptcl): Preliminary Results From a Phase 2 Study

Anaplastic, T-Cell, Non-Hodgkin's Lymphoma Presenting With Haematuria